the aid library

LIST OPTIONS

Filter

1281

Sort by:

Direction:

Download (108)

View PDF (149)

Signs and symptoms of chronic HIV disease

G. Rogers; A. Mijch; A. Brotherton ResearchGate.net (2008) C2

Article, January 2008

Download (94)

View PDF (154)

Health Advisory for Elderly Population of India during COVID19 Pandemic

Ministery of Health and Family Welfare - Government of India (2020) C2

Elderly people are at a higher risk of COVID-19 infection due to their decreased immunity and body reserves, as well as multiple associated comorbidities like diabetes, hypertension, chronic kidney disease and chronic obstructive pulmonary disease. Also, course of disease tends to be more severe in ... more

Download (72)

View PDF (293)

Air Pollution - WHO

World Health Organisation (WHO) (2022) C_WHO

Accessed on 06.03.2022 Air pollution is contamination of the indoor or outdoor environment by any chemical, physical or biological agent that modifies the natural characteristics of the atmosphere. Household combustion devices, motor vehicles, industrial facilities and forest fires are common sou... more

Download (77)

View PDF (940)

Air pollution and diabetes: it's time to get active!

O'Donovan, G.; Cadena-Gaitán, C. (2018) CC

Cardiovascular disease, diabetes, chronic obstructive pulmonary disease, cancers, and other non-communicable diseases are among the leading causes of morbidity and mortality in low-income, middle-income, and high-income countries, and The Lancet Taskforce recently made the case for investing in non-... more

Download (105)

View PDF (92)

De Diagnóstico y tratamiento de la enfermedad Pulmonar Obstructiva Crónica Guía de Práctica Clínica Nacional - 2016

Ministerio de Salud Argentina (2016) C2

El objetivo es proveer al equipo de salud, una guía de diagnóstico y terapéutica clínica, tanto farmacológica como no farmacológica, con recomendaciones basadas en evidencia de la mejor calidad disponible y adaptada al marco local. Los usuarios de la Guía son todos los integrantes del ... more

Download (97)

View PDF (395)

Molecular and Clinical Aspects of Chronic Manifestations in Chagas Disease: A State-of-the-Art Review

Medina-Rincón, G.; Gallo-Bernal, S.; Jiménez, P.; et al. (2021) CC

Pathogens . 2021 Nov 16;10(11):1493.doi: 10.3390/pathogens10111493 .Chronic manifestations of Chagas disease present as disabling and life-threatening condi-tions affecting mainly the cardiovascular and gastrointestinal systems. Although meaningful research has outlined the different molecular mech... more

Download (244)

View PDF (328)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (12)

View PDF (11)

The availability, cost, and affordability of essential medicines for asthma and COPD in low-income and middle-income countries: a systematic review

Stolbrink, M.; Thomson, H.; Hadfield, R.M. et al. The Lancet Global Health (2022) CC

Background: Asthma and chronic obstructive pulmonary disease (COPD) cause a considerable burden of morbidity and mortality in low-income and middle-income countries (LMICs). Access to safe, effective, quality-assured, and affordable essential medicines is variable. We aimed to review the existing ... more

Download (10)

View PDF (13)

Under- and over-diagnosis of COPD: a global perspective

Ho T., Cusack R.P., Chaudhary N. et al. Breathe, part of the European Respiratory Society (ERS) (2019) CC2

The article "Under- and over-diagnosis of COPD: a global perspective" reviews the worldwide variation in the prevalence of chronic obstructive pulmonary disease (COPD) and issues related to its misdiagnosis. It highlights that COPD is under-diagnosed due to factors such as limited access to spiromet... more

Download (18)

View PDF (22)

The silent epidemic of COPD in Africa

Salvi S. The Lancet Global Health (2015) CC2

The article "The silent epidemic of COPD in Africa" discusses the under-recognized yet significant prevalence of chronic obstructive pulmonary disease (COPD) in Africa. Despite being the third leading cause of death worldwide, COPD remains poorly studied and largely unknown in sub-Saharan Africa. Th... more

Download (16)

View PDF (20)

Health and Quality of Life Outcomes

Van der Molen, T.; Willemse, B.; Schokker, S.; et al. Health and Quality of Life Outcomes (2003) CC2

The new Global Obstructive Lung Disease (GOLD) guidelines advice to focus treatment in Chronic Obstructive Pulmonary Disease (COPD) on improvement of functional state, prevention of disease progression and minimization of symptoms. So far no validated questionnaires are available to measure symptom ... more

Download (16)

View PDF (17)

COPD in Asia* Where East Meets West

Wan, C.; Tze, P. CHEST (2008) CC2

The article investigates the global burden and risk factors of chronic obstructive pulmonary disease (COPD). It emphasizes that COPD is a leading cause of morbidity and mortality worldwide, with significant health and economic impacts. The study identifies smoking as the primary risk factor, but als... more

Download (19)

View PDF (14)

Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps

Blanco, I.; Diego, I.; Bueno, P. et al. (2019) CC2

Existing data on chronic obstructive pulmonary disease (COPD) prevalence are irregularly distributed around the world, and in many geographic regions data are scarce or even nonexistent. This fact hinders the implementation of adequate preventive and therapeutic interventions to reduce the high burd... more

Download (6)

View PDF (6)

The COPD Foundation - South Africa

The COPD Foundation - South Africa The COPD Foundation - South Africa (2024) CC2

The website for the COPD Foundation in South Africa provides information and resources dedicated to raising awareness, improving education, and supporting individuals affected by Chronic Obstructive Pulmonary Disease (COPD). Managed by the C.A.R.E.S. Group (COPD Advocacy, Research, Education, Suppor... more

Download (6)

View PDF (7)

The silent epidemic of COPD in Africa 2015

Salvi, S. The Lancet Global Health (2015) CC2

The article from The Lancet Global Health discusses the "silent epidemic" of chronic obstructive pulmonary disease (COPD) in Africa, emphasizing its status as an under-recognized yet significant health issue. Although COPD is the third leading cause of death globally, it remains largely overlooked i... more

Download (8)

View PDF (10)

COPD Foundation Educational Materials - COPD 101: Understanding the Basic of COPD

COPD Foundation COPD Foundation (2022) CC2

The document "COPD 101: Understanding the Basics" from the COPD Foundation provides foundational knowledge about chronic obstructive pulmonary disease (COPD). It explains what COPD is, common symptoms, risk factors, diagnosis methods, and treatment options, including medications and lifestyle change... more

Download (7)

View PDF (11)

COPD Foundation Educational Materials - EPOC 101: Comprender lo básico de la EPOC

COPD Foundation COPD Foundation (2022) CC2

Download (31)

View PDF (23)

Vigilância global, prevenção e controlo das doenças respiratórias crónicas: uma abordagem integradora

Bousquet, J.; Khaltaev, N. (2007) C_WHO

Chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease, kill more than four million people every year and affect hundreds of millions more. These diseases erode the health and well-being of the patients and have a negative impact on families and societies. Women ... more

Download (20)

View PDF (19)

Access to essential respiratory medications remains elusive in LMICs

Karmali, D.; Siddharthan, T. (2022) CC

Over 90% of the morbidity and mortality related to chronic obstructive pulmonary disease (COPD) and asthma occurs in low-income and middle-income countries (LMICs) due to well documented factors including decreased access to screening, trained health professionals, and therapies for disease manageme... more

Download (19)

View PDF (22)

Ambient air pollution and non-communicable respiratory illness in sub-Saharan Africa: a systematic review of the literature

Glenn, B. E.; Espira, L. M.; Larson, M. C.; Larson, P. S. BMC (2022) CC2

Aerosol pollutants are known to raise the risk of development of non-communicable respiratory diseases (NCRDs) such as asthma, chronic bronchitis, chronic obstructive pulmonary disease, and allergic rhinitis. Sub-Saharan Africa’s rapid pace of urbanization, economic expansion, and population growt... more